A comparative study of deep learning-based network model and conventional method to assess beach debris standing-stock.

The conventional survey of marine debris standing-stock has various drawbacks such as high cost and inaccuracy because the total amount of debris in the whole beach is inferred using the results of the manual investigation in selected narrow areas. To overcome the disadvantages, an automatic detection method using a deep learning-based network model was developed to detect and quantify the beach debris. The network model developed in this study classified items with a precision of 0.87 (87%) mAP and showed <5% error compared to actual survey. This study is the first fieldwork in Korea that shows the difference between automatic and conventional methods to predict the beach debris standing-stock. The results provide essential information for the development of effective beach debris management systems and policies.

Endowing antifouling properties on metal substrata by creating an artificial barrier layer based on scalable metal oxide nanostructures.

Here, by creating different types of artificial barrier layer against bacterial attachment, anti-biofouling properties were endowed on three metallic surfaces - aluminum, stainless steel and titanium. To each metallic surface, a tailored chemical oxidation process was applied to grow scalable oxide structures with an additional appropriate coating, resulting in three different types of anti-biofouling barrier, a thin water film, an air layer and an oil layer. Fluorescence images of the attached bacteria showed that the water layer improved the anti-biofouling performance up to 8-12 h and the air layer up to 12-24 h, comparable with the lifetime of the air layer. In comparison, the oil layer exhibited the best anti-biofouling performance by suppressing the fouled area by < 10% up to 72 h regardless of the substratum type. The present work provides simple, low-cost, scalable strategies to enhance the anti-biofouling performance of industrially important metallic surfaces. [Formula: see text].

Effect of a Dose-Escalation Regimen for Improving Adherence to Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.

BACKGROUND: The adverse effects of the phosphodiesterase-4 inhibitor roflumilast, appear to be more frequent in clinical practice than what was observed in chronic obstructive pulmonary disease (COPD) clinical trials. Thus, we designed this study to determine whether adverse effects could be reduced by starting roflumilast at half the dose, and then increasing a few weeks later to 500 µg daily. METHODS: We retrospectively investigated 85 patients with COPD who had taken either 500 µg roflumilast, or a starting dose of 250 µg and then increased to 500 µg. We analyzed all adverse events and assessed differences between patients who continued taking the drug after dose escalation and those who had stopped. RESULTS: Adverse events were reported by 22 of the 85 patients (25.9%). The most common adverse event was diarrhea (10.6%). Of the 52 patients who had increased from a starting dose of 250 µg roflumilast to 500 µg, 43 (82.7%) successfully maintained the 500 µg roflumilast dose. No difference in factors likely to affect the risk of adverse effects, was detected between the dose-escalated and the discontinued groups. Of the 26 patients who started with the 500 µg roflumilast regimen, seven (26.9%) discontinued because of adverse effects. There was no statistically significant difference in discontinuation rate between the dose-escalated and the control groups (p=0.22). CONCLUSION: Escalating the roflumilast dose may reduce treatment-related adverse effects and improve tolerance to the full dose. This study suggests that the dose-escalated regimen reduced the rate of discontinuation. However, longer-term and larger-scale studies are needed to support the full benefit of a dose escalation strategy.

An exploratory study; the therapeutic effects of premixed activated charcoal-sorbitol administration in patients poisoned with organophosphate pesticide.

OBJECTIVE: The effects of activated charcoal (AC) mixed with cathartics for gastric decontamination in the management of organophosphate (OP) poisoning remain unknown due to limited clinical evidence. This exploratory study assessed the effectiveness of premixed AC-sorbitol as a treatment for OP poisoning. MATERIALS AND METHODS: This retrospective observational case study included patients who either did not receive AC-sorbitol or received a single dose of AC-sorbitol within 24 h after OP ingestion. The patients were divided into three groups: no AC-sorbitol treatment, patients who received AC-sorbitol within 1 h of OP ingestion, and patients who received AC-sorbitol more than 1 h after OP ingestion. Mortality, the development of respiratory failure, and the duration of mechanical ventilation were used as outcome measurements for effectiveness, whereas aspiration pneumonia and electrolyte imbalance were employed as safety measurements. RESULT: Among 262 patients with OP poisoning, 198 were included. Of these, 133 patients did not receive AC-sorbitol, whereas 14 and 51 patients received AC-sorbitol within 1 h or more than 1 h after ingestion, respectively. The time from ingestion to hospital arrival and time from ingestion to administration of atropine and pralidoxime differed among the groups, whereas other characteristics, including age, amount ingested, and type of ingested OP, were similar among the groups. Univariate and multivariate analysis demonstrated that the administration of AC-sorbitol was not associated with outcome measures for effectiveness and did not significantly increase either aspiration pneumonia or electrolyte imbalances during hospitalization. DISCUSSION AND CONCLUSION: The administration of AC-sorbitol exerted neither beneficial nor harmful effects on the outcomes of OP-poisoned patients regardless of the time from OP ingestion to administration, compared with those of patients who did not receive AC-sorbitol. However, this study enrolled a small number of patients who received AC-sorbitol; further qualified trials with a sufficient number of patients are therefore needed.